JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation

被引:0
|
作者
H Zhan
Y Ma
C H S Lin
K Kaushansky
机构
[1] Northport VA Medical Center,Division of Hematology
[2] Stony Brook University,Oncology, Department of Medicine
[3] Stony Brook University,Department of Medicine, Division of Hematology
[4] Office of the Sr Vice President,Oncology
[5] Health Sciences,Department of Pathology
[6] Stony Brook Medicine,undefined
来源
Leukemia | 2016年 / 30卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain incomplete. One hallmark feature of the marrow in patients with MPNs is megakaryocyte (MK) hyperplasia. We report here that mice bearing a human JAK2V617F gene restricted exclusively to the MK lineage develop many of the features of a MPN. Specifically, these mice exhibit thrombocytosis, splenomegaly, increased numbers of marrow and splenic hematopoietic progenitors and a substantial expansion of HSPCs. In addition, wild-type mice transplanted with cells from JAK2V617F-bearing MK marrow develop a myeloproliferative syndrome with thrombocytosis and erythrocytosis as well as pan-hematopoietic progenitor and stem cell expansion. As marrow histology in this murine model of myeloproliferation reveals a preferentially perivascular localization of JAK2V617F-mutant MKs and an increased marrow sinusoid vascular density, it adds to accumulating data that MKs are an important component of the marrow HSPC niche, and that MK expansion might indirectly contribute to the critical role of the thrombopoietin/c-Mpl signaling pathway in HSPC maintenance and expansion.
引用
收藏
页码:2332 / 2341
页数:9
相关论文
共 50 条
  • [31] Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F
    Lundberg, Pontus
    Takizawa, Hitoshi
    Kubovcakova, Lucia
    Guo, Guoji
    Hui Hao-Shen
    Dirnhofer, Stephan
    Orkin, Stuart H.
    Manz, Markus G.
    Skoda, Radek C.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (11): : 2213 - 2230
  • [32] Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders
    J-J Kiladjian
    N Elkassar
    B Cassinat
    G Hetet
    S Giraudier
    N Balitrand
    C Conejero
    J Briere
    P Fenaux
    C Chomienne
    B Grandchamp
    Leukemia, 2006, 20 : 1181 - 1183
  • [33] JAK2, the JAK2 V617F mutant and cytokine receptors
    Staerk, J.
    Kallin, A.
    Royer, Y.
    Diaconu, C. C.
    Dusa, A.
    Demoulin, J.-B.
    Vainchenker, W.
    Constantinescu, S. N.
    PATHOLOGIE BIOLOGIE, 2007, 55 (02): : 88 - 91
  • [34] Cell Competition between Wild-Type and JAK2V617F Mutant Cells Prevents Disease Relapse after Stem Cell Transplantation in a Murine Model of Myeloproliferative Neoplasm
    Zhang, Haotian
    Castiglione, Melissa
    Zheng, Lei
    Zhan, Huichun
    BLOOD, 2021, 138
  • [35] Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative neoplasm
    Haotian Zhang
    Melissa Castiglione
    Lei Zheng
    Huichun Zhan
    Experimental Hematology & Oncology, 10
  • [36] Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative neoplasm
    Zhang, Haotian
    Castiglione, Melissa
    Zheng, Lei
    Zhan, Huichun
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [37] JAK2V617F Hematopoietic Stem and Progenitors Are More Resistant to Chronic Blockage of IL-10 Signaling in a Murine Model of Myeloproliferative Neoplasms
    Lai, Hew Yeng
    Trieu, Tiffany
    Han, Tiffany
    Brooks, Stefan
    Craver, Brianna
    Ramanathan, Gajalakshmi
    Fleischman, Angela G.
    BLOOD, 2019, 134
  • [38] JAK2V617F Hematopoietic Stem Cells Exhibit a Blunted Response to Acute Inflammation
    Craver, Brianna
    Lai, Hew Yeng
    Morse, Sarah
    Brooks, Stefan
    Kim, Daniel
    Fleischman, Angela G.
    BLOOD, 2017, 130
  • [39] Inhibition of JAK2 V617F-Induced erythroid skewing of hematopoietic stem cell differentiation with a selective JAK2 antagonist.
    Geron, Ifat
    Barroga, Charlene
    Gotlib, Jason
    Kavalerchik, Edward
    Abrahamsson, Annelie
    Goff, Daniel
    Cacalano, Nicholas
    Hood, John
    Soll, Richard
    Noronha, Glenn
    Tefferi, Ayalew
    Weissman, Irving L.
    Kaushansky, Kenneth
    Jamieson, Catriona
    BLOOD, 2006, 108 (11) : 1033A - 1033A
  • [40] Characterizing the Disease-Initiating Cell Population In a Murine Model of Jak2V617F+Myeloproliferative Neoplasm
    Mullally, Ann
    Lane, Steven W.
    Poveromo, Luke
    Al-Shahrour, Fatima
    Kutok, Jeffery
    Ebert, Benjamin L.
    BLOOD, 2010, 116 (21) : 144 - 145